Procaps Group S.A (PROC) | Stock Overview & Key Data
Procaps Group S.A Performance Comparison
Stock Range
Today's Range
Low: $1.14
High: $1.14
on September 30, 2025
52 Week Range
Low: $0.01
High: $3.78
on December 17, 2024
All-Time High: $11.98 on October 18, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$128.6M
EPS
0.42
P/E Ratio (TTM)
1.53
Forward P/E
3.74
P/B Ratio
3.04
PEG Ratio
-0.02
Div. Yield
N/A
ROE
-2,265.18%
Beta
N/A
Debt to Equity
7.54
Financial Highlights
Profitability
Gross Margin
57.77%
Operating Margin
19.14%
Profit Margin
58.44%
Returns and Earnings
Return on Assets (TTM)
9.24%
Return on Equity (TTM)
-2,265.18%
EBITDA
$105.7M
Net Income (TTM)
$42.5M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$3.63
Quarterly Revenue Growth (YoY)
7.59%
Quarterly Earnings Growth (YoY)
7.25%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Procaps Group S.A PROC | 128.62M Micro-cap | 0.00% | 1.79% | -18.57% | -22.45% | -51.07% | -47.22% | -82.88% | -88.51% |
| Haleon Plc - ADR HLN | 41.72B Large-cap | 1.83% | -9.02% | -13.45% | -12.60% | -5.93% | -14.37% | 45.81% | 19.84% |
| United Therapeutics UTHR | 19.33B Large-cap | 4.24% | 9.54% | 50.21% | 42.01% | 23.10% | 24.59% | 114.46% | 326.34% |
| Ironwood IRWD | 230.66M Micro-cap | 26.77% | 22.90% | 117.57% | 11.81% | -62.82% | -62.56% | -84.11% | -84.65% |
| BioAge Labs BIOA | 212.23M Micro-cap | 13.03% | 26.88% | 39.15% | 69.05% | 6.12% | -73.05% | -71.90% | -71.90% |
| Journey Medical DERM | 186.80M Micro-cap | 5.80% | 2.53% | 3.69% | 16.99% | 82.50% | 11.79% | 208.02% | -26.26% |
Ownership & Short Interest
Insider Ownership
N/A
Institutional Ownership
N/A
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
273
Average 90-Day Volume
106
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is PROC's 52-week high and low?
- In the last 52 weeks, Procaps Group S.A reached a high of $3.78 (on December 17, 2024) and a low of $0.01 (on N/A).
- What is the market cap and P/E ratio for PROC?
- Curious about Procaps Group S.A's size and valuation? Its market capitalization stands at 128.62M. When it comes to valuation, the P/E ratio (trailing twelve months) is 1.53, and the forward P/E (looking ahead) is 3.74.
- Does PROC pay dividends? If so, what's the yield?
- As for dividends, Procaps Group S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Procaps Group S.A's main competitors or similar companies to consider before investing?
When looking at Procaps Group S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Haleon Plc - ADR
HLN41.72B Healthcare Drug Manufacturers - Specialty & Generic -14.37% 45.81% United Therapeutics
UTHR19.33B Healthcare Drug Manufacturers - Specialty & Generic 24.59% 114.46% Ironwood
IRWD230.66M Healthcare Drug Manufacturers - Specialty & Generic -62.56% -84.11% BioAge Labs
BIOA212.23M Healthcare Drug Manufacturers - Specialty & Generic -73.05% -71.90% Journey Medical
DERM186.80M Healthcare Drug Manufacturers - Specialty & Generic 11.79% 208.02% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Procaps Group S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Procaps Group S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -2,265.18%, the Debt to Equity ratio from the most recent quarter is 7.54, and its Gross Profit Margin stands at 57.77%.
- What is the recent revenue and earnings growth for PROC?
- Looking at Procaps Group S.A's growth, its revenue over the trailing twelve months (TTM) was $410M. Compared to the same quarter last year (YoY), quarterly revenue grew by 7.59%, and quarterly earnings saw a YoY growth of 7.25%.
- How much of PROC stock is held by insiders and institutions?
- Wondering who owns Procaps Group S.A stock? Company insiders (like executives and directors) hold about N/A of the shares, while institutional investors (such as mutual funds and pension funds) own approximately N/A.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.